Industry veteran joins Auxilium Pharmaceuticals
Adrian Adams succeeds Armando Anido at the US firm
Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as chairman and ceo of Neurologix, a biotechnology company engaged in the development of gene therapies for disorders of the brain and central nervous system. Prior to that, he was president and ceo of Inspire Pharmaceuticals, where he oversaw the development and commercialisation of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co.
Before joining Inspire, Adams was president and ceo of Sepracor until its acquisition by Dainippon Sumitomo Pharma Co in 2010. Prior to this, he was president and ceo of Kos Pharmaceuticals from 2002 until the company was acquired by Abbott Laboratories in 2006.
Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).
You may also like
Pharmaceutical
Optimising process steps and performance with agitated Nutsche filter-dryers
Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
Sustainability
ACG Packaging Materials becomes first pharma packaging firm to join WEF Lighthouse Network
The company has joined the World Economic Forum’s Global Lighthouse Network after its Shirwal facility was named a Lighthouse site, making it the world’s first pharmaceutical packaging company to receive the recognition for smart, sustainable manufacturing
Pharmaceutical
testo Saveris 1 update automates environmental monitoring workflows for pharma compliance
New features include automated workflows for efficient environmental monitoring, approvals for secure and compliant changes, and more flexible control of webhooks, as well as further improvements in performance, transparency and usability
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies